|
| Press Releases |
|
 |
|
| Friday, October 30, 2020 |
|
|
Avance Clinical Wins MasterControl 2020 Innovation Excellence Award |
| The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical today accepted the MasterControl 2020 Innovation Excellence Award in a virtual ceremony. more info >> |
|
| Wednesday, October 28, 2020 |
|
|
Biotechs get scalable early to late phase clinical offering from Avance Clinical and Cromos Pharma - announced at Bio-Europe 2020 |
| Two dominant regional contract research organizations (CRO), Avance Clinical and Cromos Pharma, with operations in Australia and Central/Eastern Europe, respectively, are successfully collaborating on a scalable clinical solution for biotechs. more info >> |
|
| Tuesday, September 22, 2020 |
|
|
Avance Clinical Announces Expanded eClinical Solutions for Biotech Clinical Trials at BioPharm America |
| The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical has expanded its eClinical solutions offering, with advanced digital clinical tools for enhanced patient engagement, visibility, data capture, and analysis. www.avancecro.com/eclinical-solutions more info >> |
|
| Friday, September 4, 2020 |
|
|
Avance Clinical Client Immunic, Inc. Announced Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function |
| The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that its client Immunic Therapeutics has announced dosing of the first healthy volunteer in the company's phase 1 clinical program of IMU-856, an novel treatment for patients suffering from gastrointestinal diseases, including diarrhea-predominant irritable bowel syndrome, ulcerative colitis and Crohn's disease. more info >> |
|
| Wednesday, July 22, 2020 |
|
|
Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study, Atossa's Second COVID-19 Therapeutic Development Program |
| The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been contracted to conduct a clinical study of Atossa Therapeutics' proprietary drug candidate AT-301, to be administered by nasal spray. Avance has successfully completed multiple clinical studies of Atossa's proprietary Endoxifen. more info >> |
|
| Thursday, July 9, 2020 |
|
|
Avance Clinical Wins Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award |
| The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award at a global virtual awards ceremony overnight. more info >> |
|
| Tuesday, June 9, 2020 |
|
|
TrialTrove Data Shows Australia is Open for Business says Avance Clinical at BIO Digital 2020 |
| The leading Australian CRO for biotechs, Avance Clinical announced at BIO Digital today that Australia currently has 2,413 trials planned or ongoing. more info >> |
|
| Thursday, April 9, 2020 |
|
|
Australian CRO Avance Clinical Designated an Essential Service as Strong Demand from Sponsors Continues Amid COVID-19 Crisis |
| Leading Australian CRO Avance Clinical said there was still strong demand from Asian and US sponsors, and commended Australian sites that had risen to the challenge to deliver for Avance Clinical clients during this difficult time. more info >> |
|
| Thursday, April 2, 2020 |
|
|
Avance Clinical on Top Reasons APAC Biotech Clients Choose Australia for Clinical Trials |
| Leading Australian CRO Avance Clinical today detailed the top reasons its APAC biotechs selected Australia for their early phase clinical trials, based on client onboarding feedback. more info >> |
|
| Friday, March 20, 2020 |
|
|
Australian CRO, Avance Clinical is Uniquely Positioned for COVID-19 Vaccines and Therapies Clinical Trials |
| Australian CRO Avance Clinical said today that Australia's fast regulatory approval environment, key opinion leader expertise and high-quality clinical research sites, as well as the attractive 40% Government rebate on clinical trial spend, means Avance is uniquely positioned to deliver rapid results for urgent COVID-19 trials. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Hitachi High-Tech Announces the SU9600: Next-Generation Ultrahigh-Resolution Scanning Electron Microscope with High Throughput
Oct 31, 2025 0:45 JST
|
|
|
Sharp to Introduce AQUOS sense10 Smartphone
Oct 31, 2025 0:27 JST
|
|
|
Fujitsu to provide digital ticketing service for NTT DOCOMO's new d ticket platform
Oct 31, 2025 0:07 JST
|
|
|
EESystem Triumphs Again: Courts Deem Jason Shurka's Claims "Baseless" and "Futile"
Oct 31, 2025 21:45 HKT/SGT
|
|
|
Autumn Lighting Fair, Outdoor and Tech Light Expo, Eco Expo Asia draw some 62,000 buyers
Oct 31, 2025 19:56 HKT/SGT
|
|
|
Saudi Arabia Assumes Chairmanship of INTOSAI
Oct 31, 2025 19:45 HKT/SGT
|
|
|
T-RIZE Strategically Collaborates with Republic and Canton to Launch the First New Construction Real Estate Equity Tokenization Deal on Canton Network, phase one of a $200M plan
Oct 31, 2025 15:50 HKT/SGT
|
|
|
IPO Watch - High-Margin International Business Scales Up Rapidly: Unpacking Hithium Energy Storage's Global Expansion Ambition Behind its Push for a Hong Kong Listing 
Oct 31, 2025 15:20 HKT/SGT
|
|
|
CIMC Group Announces the First Three Quarter Results for 2025
Oct 31, 2025 14:16 HKT/SGT
|
|
|
Hong Kong delegation concludes mission in Riyadh
Oct 31, 2025 11:19 HKT/SGT
|
|
|
The Executive Centre Unveils New Premium Flexible Workspace at One IFC, Central Hong Kong
Oct 31, 2025 09:19 HKT/SGT
|
|
|
Doubleview Gold Corp Announces Non-Brokered Private Placement of Flow-Through Shares at $1.00 per share along with Non-Flow-Through Units
Oct 31, 2025 09:09 HKT/SGT
|
|
|
HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus
Oct 31, 2025 9:30 JST
|
|
|
TruMerit's Peter Preziosi Elected President of the Conference of NGOs in Consultative Relationship With the United Nations
Oct 31, 2025 04:00 HKT/SGT
|
|
|
MHI and Nippon Shokubai to Develop Ammonia Cracking System for NEDO's "Development of Technologies for Building a Competitive Hydrogen Supply Chain" Project
Oct 30, 2025 23:14 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
